Amarin Corp. plc, of Dublin, recognized $26.4 million in net product revenue from Vascepa (icosapent) sales and $26.6 million in total revenue in the fourth quarter of 2015, reflecting a 24 percent increase over the previous quarter and 60 percent increase over the same quarter of the previous year's net product sales, and leading to full-year net product revenue of $81 million and full-year total revenue of $81.8 million, increases of 49 percent and 51 percent, respectively, over 2014.